Analysis of efficacy and prognosis of neoadjuvant chemotherapy and （or） surgery plus radiotherapy for hypopharyngeal squamous cell carcinoma / 临床耳鼻咽喉头颈外科杂志

Objective:To analyze the risk factors that affect the prognosis of patients with hypopharyngeal squamous cell carcinoma（HPSCC） and to compare the efficacy of surgical resection followed by adjuvant radiotherapy（SR） with that of neoadjuvant therapy consisting of platinum-based chemotherapy and fluorouracil combined with either cetuximab or nimotuzumab, followed by SR. The study also aimed to evaluate the overall survival（OS） of patients, their postoperative eating function, tracheostomy decannulation rate, and tumor response to the two neoadjuvant chemotherapies. Methods:A retrospective analysis was performed on the medical records of HPSCC patients who received SR or neoadjuvant therapy followed by SR treatment at the Shanghai General Hospital from 2012 to 2019 and had not undergone any prior treatment. The prognostic factors were analyzed, and the survival analysis of patients who underwent SR treatment with two neoadjuvant chemotherapy regimens was performed. Results:A total of 108 patients were included in the study. The results of the univariate analysis showed that gender（P=0.850） had no significant correlation with the survival rate of HPSCC patients who underwent SR. However, age, smoking history, alcohol consumption history, platelet-to-lymphocyte ratio（PLR）, neutrophil-to-lymphocyte ratio（NLR）, T stage, N stage, neoadjuvant therapy with either cetuximab or nimotuzumab combined with platinum-based chemotherapy and fluorouracil, and histological grade were significantly associated with prognosis（P<0.05）. The multivariate analysis revealed that smoking history, histological grade, and neoadjuvant therapy with either cetuximab or nimotuzumab combined with platinum-based chemotherapy and fluorouracil were independent risk factors affecting the prognosis of HPSCC（P<0.05）. Patients who received neoadjuvant therapy had longer OS than those who underwent SR only（P<0.001）. There was no significant difference in tumor response to the two neoadjuvant therapies and in OS（P>0.05）, and there was no significant difference in the rate of oral feeding and tracheostomy decannulation among the three treatment groups（P>0.05）. Conclusion:Univariate analysis showed that age at tumor onset, smoking history, alcohol consumption history, NLR, PLR, T stage, N stage, whether receiving neoadjuvant chemotherapy, and pathological grade were associated with the prognosis of HPSCC patients receiving SR treatment. Multivariate analysis showed that smoking history, pathological grade, and neoadjuvant chemotherapy were independent risk factors affecting the prognosis. Neoadjuvant chemotherapy with cetuximab or nimotuzumab can prolong the OS of patients, providing a certain basis and reference for the treatment of HPSCC.

Expression and clinical pathological implications of carbonic anhydrase 9 and P glycoprotein in laryngeal squamous cell carcinoma / 临床耳鼻咽喉头颈外科杂志

OBJECTIVE@#To identify the difference of CA IX and P-gp expression level between laryngeal squamous cell carcinoma (LSCC) and benign tissues, evaluate the relationship of these two proteins in LSCC, and their correlation with clinical and pathological features.@*METHOD@#Immunohistochemical detection of CA IX and P-gp were performed in 47 cases of LSCC and 20 cases of vocal cord polyps.@*RESULT@#Overexpression of CA IX and P-gp both in LSCC and in vocal cord polyp (P < 0.05) were confirmed, with a correlation between the two proteins in LSCC (r = 0.324, P < 0.05). The expression of CA IX was related to clinical staging and lymph node metastasis in LSCC (P < 0.05). While P-gp was related to clinical staging and histological grading in LSCC (P < 0.05).@*CONCLUSION@#The overexpression of CA IX and P-gp may play a role in LSCC progression.

Expressions of EGFR,COX-2 and P63 in non-small cell lung cancer and their significance / 第三军医大学学报

Objective To investigate the expressions of epidermal growth factor receptor (EGFR), cyclooxygenase-2 (COX-2) and P63 protein in non-small cell lung cancer (NSCLC) and their relationship with TNM staging and lymph node metastasis of NSCLC. Methods Seventy-eight paraffin-embedded specimens of NSCLC from 1998-2005 were collected in this study. Inclusion criteria included no chemotherapy or radiotherapy before operation. Pathological diagnosis was made after operation: 43 squamous carcinoma and 35 adenocarcinoma, 45 with lymph node metastasis and 33 without, 13 in stage Ⅰ, 19 in stage Ⅱ, 28 in stage Ⅲ and 18 in stage Ⅳ. The expressions of EGFR, COX-2 and P63 were determined by immunohistochemical staining (S-P). Results The expression rates of EGFR, COX-2 and P63 were 65.4% (51/78), 61.5% (48/78) and 56.4% (44/78) respectively in 78 cases of NSCLC. Significant difference in the expressions of COX-2 and P63 was found between squamous carcinoma and adenocarcinoma (P0.05). The positive rate of EGFR and COX-2 protein expressions in NSCLC of stage Ⅲ-Ⅳ and NSCLC with lymph node metastasis was significantly higher than that in stage Ⅰ-Ⅱ and NSCLC without lymph node metastasis (P0.05). Conclusion Over-expressions of EGFR and COX-2 may play an important role in invasion and metastasis of NSCLC. COX-2 and P63 may be valuable markers in differentiating pulmonary squamous cell carcinoma from pulmonary adenocarcinoma.